A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex.
The Ca(2+) dependent interaction between troponin I (cTnI) and troponin C (cTnC) triggers contraction in heart muscle. Heart failure is characterized by a decrease in cardiac output, and compounds that increase the sensitivity of cardiac muscle to Ca(2+) have therapeutic potential. The Ca(2+)-sensitizer, levosimendan, targets cTnC; however, detailed understanding of its mechanism has been obscured by its instability. In order to understand how this class of positive inotropes function, we investigated the mode of action of two fluorine containing novel analogs of levosimendan; 2',4'-difluoro(1,1'-biphenyl)-4-yloxy acetic acid (dfbp-o) and 2',4'-difluoro(1,1'-biphenyl)-4-yl acetic acid (dfbp). The affinities of dfbp and dfbp-o for the regulatory domain of cTnC were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp. Dfbp-o also increased the affinity of cTnI for cTnC. Dfbp-o increased the Ca(2+)-sensitivity of demembranated cardiac trabeculae in a manner similar to levosimendan. The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of cTnI. In the absence of cTnI, docking localized dfbp-o to the same position in the hydrophobic groove of cTnC. The structural and functional data reveal that the levosimendan class of Ca(2+)-sensitizers work by binding to the regulatory domain of cTnC and stabilizing the pivotal cTnC-cTnI regulatory unit via a network of hydrophobic and electrostatic interactions, in contrast to the destabilizing effects of antagonists such as W7 at the same interface.
Robertson
Ian M
IM
Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.
Sun
Yin-Biao
YB
Li
Monica X
MX
Sykes
Brian D
BD
D000818:Animals; D002118:Calcium; D006801:Humans; D006835:Hydrazones / Q000737:chemistry* / Q000494:pharmacology*; D066298:In Vitro Techniques; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism*; D017433:Protein Structure, Secondary; D011724:Pyridazines / Q000737:chemistry* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D000077464:Simendan; D055672:Static Electricity; D013329:Structure-Activity Relationship; D017186:Titrimetry; D019209:Troponin C / Q000737:chemistry* / Q000378:metabolism*; D019210:Troponin I / Q000737:chemistry* / Q000378:metabolism*
D006835:Hydrazones; D008024:Ligands; D011724:Pyridazines; D019209:Troponin C; D019210:Troponin I; D000077464:Simendan; D002118:Calcium
Curr Top Med Chem. 2006;6(14):1473-82
16918463
J Biomol NMR. 1994 Sep;4(5):603-14
22911360
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5140-5
10792039
Eur Biophys J. 2002 Jul;31(4):245-56
12122471
J Comput Chem. 2009 Dec;30(16):2785-91
19399780
J Mol Cell Cardiol. 2000 Mar;32(3):479-91
10731446
J Physiol. 2009 Jan 15;587(1):155-63
19015190
J Biomol NMR. 1995 Nov;6(3):277-93
8520220
Biochem Biophys Res Commun. 2008 Apr 25;369(1):88-99
18162171
Br J Pharmacol. 2007 Apr;150(7):826-8
17325657
Biochemistry. 2000 Oct 17;39(41):12731-8
11027154
J Biol Chem. 1994 Nov 18;269(46):28584-90
7961805
Biochemistry. 1997 Oct 7;36(40):12138-46
9315850
Biochemistry. 2008 Jul 15;47(28):7485-95
18570382
Nature. 2003 Jul 3;424(6944):35-41
12840750
Eur J Biochem. 2000 Nov;267(22):6665-72
11054120
J Biomol NMR. 1999 Mar;13(3):289-302
10212987
J Biol Chem. 2002 Aug 23;277(34):31124-33
12060657
J Am Chem Soc. 2006 Oct 4;128(39):12910-6
17002387
Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
15272157
Biochemistry. 2009 Jun 23;48(24):5541-52
19419198
Circ Res. 1995 Jul;77(1):107-13
7788868
Eur J Pharmacol. 2004 Feb 13;486(1):1-8
14751401
J Biol Chem. 1994 Sep 23;269(38):23731-5
8089144
J Biomol NMR. 2003 Dec;27(4):313-21
14512729
Arch Pharm Res. 2010 Jan;33(1):25-46
20191341
Prog Cardiovasc Dis. 2004 Nov-Dec;47(3):159-76
15736582
Drug Metab Dispos. 1990 Nov-Dec;18(6):1060-4
1981513
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5038-43
15784741
Chembiochem. 2004 May 3;5(5):637-43
15122635
Proteins. 2003 Feb 15;50(3):496-506
12557191
Methods Mol Biol. 2004;278:353-78
15318003
J Biol Chem. 2001 Mar 23;276(12):9337-43
11113122
J Biol Chem. 1998 Apr 3;273(14):8153-60
9525919
Biochemistry. 1985 Jan 15;24(2):544-50
2983759
J Biomol NMR. 1996 Dec;8(4):477-86
9008363
J Mol Cell Cardiol. 1995 Sep;27(9):1859-66
8523447
J Mol Cell Cardiol. 2010 May;48(5):925-33
20116385
Eur J Pharmacol. 2004 Feb 13;486(1):67-74
14751410
FEBS Lett. 1994 Aug 15;350(1):87-90
8062930
J Biomol NMR. 1996 Dec;8(4):492-8
20859780
Mol Cell Biochem. 2004 Nov;266(1-2):87-107
15646030
Biochemistry. 1994 Dec 6;33(48):14434-42
7981203
IUBMB Life. 2002 Dec;54(6):323-33
12665242
J Muscle Res Cell Motil. 2004;25(7):559-79
15711886
Biochemistry. 1999 Jun 29;38(26):8289-98
10387074
Circulation. 2006 Jan 17;113(2):305-15
16418450
J Cardiovasc Pharmacol. 1995 May;25(5):794-801
7630157